BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:28 PM
Sep 17, 2012
 |  BC Extra  |  Company News

India upholds compulsory license for Nexavar

India's Intellectual Property Appellate Board (IPAB) rejected a petition from Bayer AG (Xetra:BAYN) seeking a stay of an order granting Natco Pharma Ltd. (BSE:NATCO; NSE:NATCOPHAR) a compulsory license in India to manufacture and market a generic version of Bayer's kidney and liver cancer drug Nexavar sorafenib. In...

Read the full 227 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >